Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
about
Re-evaluation of various molecular targets located on CD34+CD38-Lin- leukemia stem cells and other cell subsets in pediatric acute myeloid leukemia.Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia.Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cellsEfficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.The novel structure make LDM effectively remove CD123+ AML stem cells in combination with interleukin 3.Unexpected mechanisms of action for a cytokine receptor-blocking antibody.A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosusUnderstanding of leukemic stem cells and their clinical implications.Antibodies to watch in 2017Sex chromosome loss and the pseudoautosomal region genes in hematological malignancies.Update on antigen-specific immunotherapy of acute myeloid leukemia.Novel drug therapies in myeloid leukemia.Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.Antibody-Based Treatment of Acute Myeloid Leukemia.Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments.Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation.Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.A radiolabeled antibody targeting CD123(+) leukemia stem cells - initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML.Emerging therapies for acute myeloid leukemia: translating biology into the clinic.An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.A dual role for the N-terminal domain of the IL-3 receptor in cell signalling.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.Targeting Leukemia Stem Cells in the Bone Marrow Niche.Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer.Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cellsCD16NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice
P2860
Q33429957-6B45AB5B-E7DE-4C7F-8013-61675BFCFA88Q34232877-367ECE1A-961B-4C47-AFC2-E7DDFCD87012Q35146288-2A4EF600-F319-4E82-BFF1-104BA44F6C86Q35546759-D1624F08-EEDC-4E05-B117-7A0B567362BDQ35607293-BE892C3A-0216-4425-95B9-B58E39223BD5Q35800831-9132246B-3621-4CAA-AB2C-02D6E1875D6EQ36838862-02AF7C8E-C6EA-4124-98E1-BB9C75BB264DQ36997749-D950D4E1-7EB0-4FBE-9408-098954ADEB9AQ37277281-41FD3578-0490-4B52-B34E-E49D63A83DF8Q37616010-4C1D2CAE-19A7-4C8E-8B73-E98821A605CAQ37631319-BF483F4F-DE42-4FD7-8637-B8264631C3CFQ37687827-3BC3E78B-0E54-4D7D-A02C-88F01293FD7CQ38432103-46BB4C81-373A-4551-B61E-E068D74D9548Q38510486-5B297D44-532C-4C88-B918-C78543F107D0Q38700209-98F576B0-94F5-43AD-A7BF-721D30AD4DAAQ38736778-F01B99BD-B99A-422D-A3F3-12E18E9BFC45Q38748924-A23A24BF-37A6-4563-BF7C-37C6D167EB75Q38979277-90FEA1B0-CDDB-4DD5-A31E-7B06F7395897Q39170884-FA6E946E-D234-4CF7-ABB0-2C9AB688162DQ40359787-94E6E29C-127D-42F5-898B-B010924C64EDQ41573313-72728A35-C85F-4446-8351-BEBFA156AD08Q41602590-D5D2A351-042D-4F1E-8D10-E19834D4EFB0Q41984963-75014030-FEE9-4DBA-8DE0-A18DE2E488BBQ45869295-AD8F27CF-F60A-4349-B1BE-489C54246463Q48158203-50C88242-EDA4-4288-BC10-F8E380EC17F6Q49539698-3D740ECB-FBAB-4F09-9A71-D564D5EB6B64Q51051082-29347D4C-5753-4D15-AD65-043431EE8E81Q52375473-61C4F04A-0E94-4554-A269-CAB7CB717036Q52846906-3520292B-FEA2-4DCA-B325-1C487542B43DQ55354182-81AEB385-D593-4A1D-B76C-AAB4367B5A59Q57174193-C91D3F5D-551C-42CA-985F-E2761A37EA21Q58793790-E9A648AA-8981-49F0-ABC7-D08E62D9BEE2
P2860
Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Targeting of acute myeloid leu ...... b engineered for optimal ADCC.
@en
Targeting of acute myeloid leu ...... b engineered for optimal ADCC.
@nl
type
label
Targeting of acute myeloid leu ...... b engineered for optimal ADCC.
@en
Targeting of acute myeloid leu ...... b engineered for optimal ADCC.
@nl
prefLabel
Targeting of acute myeloid leu ...... b engineered for optimal ADCC.
@en
Targeting of acute myeloid leu ...... b engineered for optimal ADCC.
@nl
P2093
P2860
P50
P356
P1433
P1476
Targeting of acute myeloid leu ...... Ab engineered for optimal ADCC
@en
P2093
C Panousis
S J Busfield
P2860
P2888
P304
P356
10.1038/LEU.2014.128
P577
2014-04-07T00:00:00Z